Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X Pub Date : 2024-09-20 DOI:10.1016/j.jvacx.2024.100561

{"title":"Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months","authors":"","doi":"10.1016/j.jvacx.2024.100561","DOIUrl":null,"url":null,"abstract":"<div><div>Thailand incorporated the hepatitis B (HepB) vaccine into the infant combination vaccine known as pentavalent wP-containing vaccines (DTwP-HB-Hib) and hexavalent aP-containing vaccines (DTaP-IPV-HB-Hib). We followed healthy children from the clinical trial (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> NCT02408926) in which children were randomly assigned to receive either pentavalent or hexavalent vaccines for their primary series (administered at 2, 4, and 6 months) and first booster vaccination (at 18 months), following the monovalent HepB vaccine at birth. Blood samples were collected to evaluate the persistence of hepatitis B surface antibody (anti-HBs) at 3, 4, 5, 6 and 7 years of age. The results showed that at 7 years of age, a higher percentage of children in the hexavalent group maintained anti-HBs levels ≥ 10 mIU/mL compared to those in the pentavalent group (86.9 % vs. 59.7 %). This study showed good persistence of anti-HBs among hexavalent-vaccinated children 5.5 years after the last dose of the HepB vaccine.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001347/pdfft?md5=7c1cd77360360e23dcac2e57338715fb&pid=1-s2.0-S2590136224001347-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Thailand incorporated the hepatitis B (HepB) vaccine into the infant combination vaccine known as pentavalent wP-containing vaccines (DTwP-HB-Hib) and hexavalent aP-containing vaccines (DTaP-IPV-HB-Hib). We followed healthy children from the clinical trial (ClinicalTrials.gov NCT02408926) in which children were randomly assigned to receive either pentavalent or hexavalent vaccines for their primary series (administered at 2, 4, and 6 months) and first booster vaccination (at 18 months), following the monovalent HepB vaccine at birth. Blood samples were collected to evaluate the persistence of hepatitis B surface antibody (anti-HBs) at 3, 4, 5, 6 and 7 years of age. The results showed that at 7 years of age, a higher percentage of children in the hexavalent group maintained anti-HBs levels ≥ 10 mIU/mL compared to those in the pentavalent group (86.9 % vs. 59.7 %). This study showed good persistence of anti-HBs among hexavalent-vaccinated children 5.5 years after the last dose of the HepB vaccine.

查看原文本刊更多论文

2 个月、4 个月、6 个月和 18 个月儿童接种六价和五价疫苗后，乙型肝炎表面抗体可持续到 7 岁

泰国将乙型肝炎（HepB）疫苗纳入了婴儿联合疫苗，即含 wP 的五价疫苗（DTwP-HB-Hib）和含 aP 的六价疫苗（DTaP-IPV-HB-Hib）。我们对临床试验（ClinicalTrials.gov NCT02408926）中的健康儿童进行了跟踪调查，在出生时接种单价乙肝疫苗后，这些儿童被随机分配接种五价或六价疫苗的初免系列（2、4、6 个月时接种）和首次加强接种（18 个月时）。采集的血液样本用于评估 3、4、5、6 和 7 岁儿童乙肝表面抗体（抗-HBs）的持久性。结果显示，与五价疫苗组相比，六价疫苗组儿童在 7 岁时保持抗-HBs 水平≥ 10 mIU/mL 的比例更高（86.9% 对 59.7%）。这项研究表明，在接种最后一剂乙肝疫苗 5.5 年后，接种六价疫苗的儿童抗乙肝病毒的持续性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine: X Multiple-

CiteScore

2.80

自引率

2.60%

发文量

102

审稿时长

13 weeks